about
Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trialEndothelial progenitor cells: what use for the cardiologist?Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromeOral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonistsA randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]Clinical review: clinical management of atrial fibrillation - rate control versus rhythm controlProtocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN893Blood pressure demographics: nature or nurture ... ... genes or environment?Peripheral arterial disease: a high risk - but neglected - disease populationEdoxaban in venous thromboembolism and stroke prevention: an appraisalEffect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysisEmerging Tools for Stroke Prevention in Atrial FibrillationEuropean Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyExpert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyRisk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysisSafety of new oral anticoagulant drugs: a perspectiveDeveloping an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, MalaysiaRed vs white thrombi: treating the right clot is crucialAtrial fibrillation: should we target platelets or the coagulation pathway?Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor interventionEffects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillationAspirin and endothelial function in hypertensionAntiplatelet and anticoagulant therapy in patients with advanced heart failurePercutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapyStroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysisPlatelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillationAnticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter, why not?Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic reviewAntiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic reviewA prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillationAngiogenesis in myocardial infarction. An acute or chronic process?Bleeding risks of antithrombotic therapyA study of platelet activation in atrial fibrillation and the effects of antithrombotic therapyThe role of aspirin in carcinogenesisAntithrombotic therapy for congestive heart failureThromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?XimelagatranViewpoint
P50
Q21132512-70E863B7-097F-47CE-9A7A-B647E6EEDC01Q21198698-749C66E7-EF5C-43E2-8059-0951F781C6A6Q22242896-B610EE01-FE61-46AF-9161-1EAB276E963FQ24623137-45F44613-A5D6-4CBA-872A-298267821D12Q24647947-1FC51284-9BF6-48CA-9BEB-7486B42892BDQ24798085-720B5B3F-DE36-470E-B751-DFF42214329CQ24800344-4671D923-D003-49C8-9527-1A252C660E0AQ24801915-11F240F3-9F04-487E-98B6-0019BBC97470Q24803842-734F9E6B-A838-49A3-AC2C-98E2E782C399Q24814570-146E512A-8D43-47F9-B344-5F934CB48371Q26751263-697A49B1-8C0F-49D9-89B0-D7A4C01683A2Q26751460-FAB1BE83-2D63-4293-8FDD-75B1941119F8Q26765023-F4F30303-A7DD-4C4F-90F9-8358DD6BA68BQ26796261-461138AE-89E7-4B10-8F82-3202CFA1D140Q26998331-1E5099DA-3CB7-4DDB-9C1F-DEB6751950B3Q27014893-D157F83F-AE0F-4CF1-93A6-1D8683DD5B5FQ27016072-AE2312AF-25DB-4655-9D08-CA754E9849AFQ27321275-B18B214D-0741-4ED1-A3B6-A458ACACE2A9Q28165662-2C9F9484-5C3E-4F12-8C86-CB545267D61BQ28166037-DDD01EF9-55C0-43AC-9A37-B955DFDF5A8FQ28168138-D29AC485-BEC6-4A73-B686-176D20B74775Q28168588-9F5779D7-0263-4E3D-B9B2-B57BFB1988B3Q28175492-B1407AA7-E0A1-483C-BB33-542F17C4D18CQ28175811-FB088D46-EB57-4E19-84FD-EBF1D31C797DQ28184902-A104FB6E-DFCB-4984-A4C8-5E3EB859A513Q28188701-6ED31BB0-E348-43DF-9D74-38D245D94AC4Q28192307-1392F225-F506-445F-9A41-F1D7A1BDA7A8Q28192920-4A7627D6-F5CC-400E-8F26-9302200D9831Q28193228-CC2054B1-6541-4AD6-9A76-332F51A4BE2EQ28193325-D2C4011D-CB6E-429F-871F-F379D8CA5141Q28193326-1636E417-739E-4325-92A4-1998856EF709Q28193502-E6DF1475-94BF-4C94-942C-8B437FFB9F47Q28193833-702CB289-1479-4A34-BF7E-3F727C73FD60Q28193922-9A67C9F4-A4E8-4126-8021-9B7979123DE9Q28194127-36A90D3C-5F62-46E4-8471-5C22032EC185Q28194254-2C3DB198-3B4D-48D7-A33D-92C362774D2BQ28194472-270826C8-0DD7-49BD-BFA5-C2CE65580113Q28195334-DBD07DE0-D878-4C99-BE00-E366CD0585C9Q28195482-C727A444-DA81-47C5-9B45-92D8608A2D19Q28195571-148F6AAD-5CE3-4132-A962-56FE932F1920
P50
description
cardioloog
@nl
researcher ORCID ID = 0000-0002-7566-1626
@en
name
Gregory Y. H. Lip
@ast
Gregory Y. H. Lip
@da
Gregory Y. H. Lip
@de
Gregory Y. H. Lip
@en
Gregory Y. H. Lip
@es
Gregory Y. H. Lip
@fo
Gregory Y. H. Lip
@fr
Gregory Y. H. Lip
@is
Gregory Y. H. Lip
@kl
Gregory Y. H. Lip
@nb
type
label
Gregory Y. H. Lip
@ast
Gregory Y. H. Lip
@da
Gregory Y. H. Lip
@de
Gregory Y. H. Lip
@en
Gregory Y. H. Lip
@es
Gregory Y. H. Lip
@fo
Gregory Y. H. Lip
@fr
Gregory Y. H. Lip
@is
Gregory Y. H. Lip
@kl
Gregory Y. H. Lip
@nb
altLabel
G Lip
@en
G Y H Lip
@en
G. Lip
@en
G. Y. H. Lip
@en
Greg Lip
@en
Gregory Lip
@en
Gregory Y H Lip
@en
prefLabel
Gregory Y. H. Lip
@ast
Gregory Y. H. Lip
@da
Gregory Y. H. Lip
@de
Gregory Y. H. Lip
@en
Gregory Y. H. Lip
@es
Gregory Y. H. Lip
@fo
Gregory Y. H. Lip
@fr
Gregory Y. H. Lip
@is
Gregory Y. H. Lip
@kl
Gregory Y. H. Lip
@nb
P214
P244
P106
P1960
cqY4wxQAAAAJ
P21
P214
P244
P31
P3762
P496
0000-0002-7566-1626
P735
P7859
lccn-n96116297